---
title: "Carlsmed, Inc. (CARL) Gets a Buy from BTIG"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290616097.md"
description: "BTIG analyst Ryan Zimmerman maintained a Buy rating on Carlsmed, Inc. (CARL) with a $23 price target, despite shares closing at $9.84. The broader analyst consensus is a Strong Buy with an average target of $18.75. Zimmerman holds a 2-star rating with a 42.31% success rate."
datetime: "2026-06-23T21:40:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290616097.md)
  - [en](https://longbridge.com/en/news/290616097.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290616097.md)
generator: "portal-rs"
---

# Carlsmed, Inc. (CARL) Gets a Buy from BTIG

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Carlsmed, Inc., with a price target of $23.00. The company’s shares closed today at $9.84.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Zimmerman is a 2-star analyst with an average return of 0.7% and a 42.31% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Solventum Corporation, and Intuitive Surgical.

Currently, the analyst consensus on Carlsmed, Inc. is a Strong Buy with an average price target of $18.75.

### Related Stocks

- [CARL.US](https://longbridge.com/en/quote/CARL.US.md)
- [GKOS.US](https://longbridge.com/en/quote/GKOS.US.md)
- [SOLV.US](https://longbridge.com/en/quote/SOLV.US.md)
- [ISRG.US](https://longbridge.com/en/quote/ISRG.US.md)

## Related News & Research

- [Roth MKM Sticks to Its Buy Rating for Coya Therapeutics, Inc. (COYA)](https://longbridge.com/en/news/296711581.md)
- [BTIG Keeps Their Buy Rating on Shift4 Payments (FOUR)](https://longbridge.com/en/news/297163377.md)
- [Alliance Global Partners Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/296781912.md)
- [JM Smucker (SJM) Receives a Buy from Jefferies](https://longbridge.com/en/news/297091842.md)
- [Maxim Group Reaffirms Their Buy Rating on Our Bond Inc (OBAI)](https://longbridge.com/en/news/296798454.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**